Published in J Clin Invest on April 13, 2006
Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell (2010) 4.99
Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res (2009) 1.68
Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res (2007) 1.67
Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. Dev Cell (2014) 1.60
The discovery of placenta growth factor and its biological activity. Exp Mol Med (2012) 1.43
Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res (2008) 1.42
Hypoxia-driven pathways in bone development, regeneration and disease. Nat Rev Rheumatol (2012) 1.36
Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. Bone (2007) 1.34
PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med (2012) 1.32
Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol (2013) 1.29
Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis. Bone (2012) 1.25
Role of hypoxia-inducible factor-1alpha in angiogenic-osteogenic coupling. J Mol Med (Berl) (2009) 1.20
Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone (2008) 1.10
Thrombospondin-2 influences the proportion of cartilage and bone during fracture healing. J Bone Miner Res (2009) 1.10
Elevated levels of placental growth factor represent an adaptive host response in sepsis. J Exp Med (2008) 0.94
Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement. Br J Cancer (2010) 0.92
Delayed bone regeneration is linked to chronic inflammation in murine muscular dystrophy. J Bone Miner Res (2014) 0.92
Hypoxia increases placenta growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J Heart Lung Transplant (2009) 0.91
MOSAIC: a multiscale model of osteogenesis and sprouting angiogenesis with lateral inhibition of endothelial cells. PLoS Comput Biol (2012) 0.91
Bone regeneration: the stem/progenitor cells point of view. J Cell Mol Med (2009) 0.90
Trpv6 mediates intestinal calcium absorption during calcium restriction and contributes to bone homeostasis. Bone (2010) 0.89
The multifaceted role of the vasculature in endochondral fracture repair. Front Endocrinol (Lausanne) (2015) 0.85
DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. Nat Commun (2012) 0.85
Mesenchymal Stem Cell-Derived Exosomes Promote Fracture Healing in a Mouse Model. Stem Cells Transl Med (2016) 0.84
Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood (2015) 0.83
Human 45,X fibroblast transcriptome reveals distinct differentially expressed genes including long noncoding RNAs potentially associated with the pathophysiology of Turner syndrome. PLoS One (2014) 0.82
Production of VEGF receptor 1 and 2 mRNA and protein during endochondral bone repair is differential and healing phase specific. J Appl Physiol (1985) (2010) 0.79
Proteolytic processing regulates placental growth factor activities. J Biol Chem (2013) 0.78
Tissue engineering strategies for promoting vascularized bone regeneration. Bone (2015) 0.78
Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies. Front Endocrinol (Lausanne) (2016) 0.78
ERK1/2 and AKT are vital factors in regulation of the migration of rat Schwann cells. J Vet Med Sci (2015) 0.78
Sustained dual release of placental growth factor-2 and bone morphogenic protein-2 from heparin-based nanocomplexes for direct osteogenesis. Int J Nanomedicine (2016) 0.77
Delayed fracture healing in tetranectin-deficient mice. J Bone Miner Metab (2013) 0.77
The vasculature: a vessel for bone metastasis. Bonekey Rep (2015) 0.75
A review of computational models of bone fracture healing. Med Biol Eng Comput (2017) 0.75
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell (1998) 9.70
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 6.73
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell (1999) 6.40
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996) 5.31
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med (2002) 4.00
Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res (2002) 3.63
Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development (2004) 3.45
Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest (2002) 3.29
Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci U S A (2004) 3.27
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem (1994) 3.14
Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest (2002) 2.59
Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development (2002) 2.57
Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology (2000) 2.51
Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev (1999) 2.46
Altered fracture repair in the absence of MMP9. Development (2003) 2.41
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res (2003) 2.35
Angiogenesis and bone repair. Drug Discov Today (2003) 2.26
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med (1999) 2.13
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med (2005) 2.10
Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res (1999) 2.02
VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res (2003) 1.82
Molecular aspects of healing in stabilized and non-stabilized fractures. J Orthop Res (2001) 1.75
Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J Clin Invest (2004) 1.72
Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. Dev Dyn (1997) 1.44
MT1-MMP-dependent, apoptotic remodeling of unmineralized cartilage: a critical process in skeletal growth. J Cell Biol (2003) 1.36
VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. Biochem Biophys Res Commun (2005) 1.29
Role of fracture hematoma and periosteum during fracture healing in rats: interaction of fracture hematoma and the periosteum in the initial step of the healing process. J Orthop Sci (2000) 1.16
Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. FASEB J (2003) 1.07
Localization and quantification of proliferating cells during rat fracture repair: detection of proliferating cell nuclear antigen by immunohistochemistry. J Bone Miner Res (1997) 1.04
The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res (1999) 1.00
Expression of cathepsins B, H, K, L, and S and matrix metalloproteinases 9 and 13 during chondrocyte hypertrophy and endochondral ossification in mouse fracture callus. Calcif Tissue Int (2000) 0.93
Bone morphogenetic protein 2 induces placental growth factor in mesenchymal stem cells. Bone (2003) 0.91
Factors in the fracture microenvironment induce primary osteoblast angiogenic cytokine production. Plast Reconstr Surg (2002) 0.87
Intensive insulin therapy in the medical ICU. N Engl J Med (2006) 22.37
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2004) 7.09
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med (2003) 5.92
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev (2008) 5.28
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics (2008) 5.06
Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell (2010) 4.99
Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax (2009) 4.86
Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest (2002) 4.38
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2012) 3.99
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest (2002) 3.90
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes (2006) 3.56
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol (2004) 3.48
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol (2002) 2.72
Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol (2002) 2.71
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Public stem cell banks: considerations of justice in stem cell research and therapy. Hastings Cent Rep (2004) 2.53
Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res (2002) 2.48
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35
Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol (2011) 2.28
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis (2013) 2.21
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J Biol Chem (2002) 2.14
NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization. J Cell Biol (2003) 2.13
Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab (2007) 2.11
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10
Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest (2012) 2.10
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Androgens and bone. Endocr Rev (2004) 2.06
Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol (2006) 2.05
Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation (2007) 2.02
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00
Role and therapeutic potential of VEGF in the nervous system. Physiol Rev (2009) 1.98
Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 1.98
Islet-derived fibroblast-like cells are not derived via epithelial-mesenchymal transition from Pdx-1 or insulin-positive cells. Diabetes (2006) 1.94
Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab (2003) 1.92
WNT5A mutations in patients with autosomal dominant Robinow syndrome. Dev Dyn (2010) 1.91
Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online (2002) 1.91
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol (2009) 1.91
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med (2004) 1.89
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88